High-dose chemotherapy in breast cancer: Dutch randomized studies

por Rodenhuis, S, van Tinteren, H, de Vries, EGE
Publicado 2001

Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response

por Hooiveld-Noeken, J.S., Fehrmann, R.S.N., de Vries, E.G.E., Jalving, M.
Publicado 2019

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate

por Garassino, M.C., Vyas, M., de Vries, E.G.E., Kanesvaran, R., Giuliani, R., Peters, S.
Publicado 2021

“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores

por Cherny, N.I., Dafni, U., Pentheroudakis, G., Piccart, M., Zygoura, P., Gyawali, B., de Vries, E.G.E.
Publicado 2022

Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience

por Latino, N.J., Galotti, M., Cherny, N.I., de Vries, E.G.E., Douillard, J.-Y., Kaidarova, D., Ilbawi, A.
Publicado 2022

Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines

por Zarkavelis, G., Amylidi, A.L., Verbaanderd, C., Cherny, N.I., Metaxas, Y., de Vries, E.G.E., Zygoura, P., Amaral, T., Jordan, K., Strijbos, M., Dafni, U., Latino, N., Galotti, M., Lordick, F., Giuliani, R., Pignatti, F., Pentheroudakis, G.
Publicado 2022

LBA79 Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study

por de Joode, K., Dumoulin, D., Tol, J., Westgeest, H., Beerepoot, L., Van den Berkmortel, F., Mutsaers, P., van Diemen, N., Visser, O., Bloemendal, H.J., van Laarhoven, H., Hendriks, L., Haanen, J.B.A.G., de Vries, E.G.E., Dingemans, A-M.C., Van der Veldt, A.
Publicado 2020

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

por Gyawali, B., de Vries, E.G.E., Dafni, U., Amaral, T., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez-Roca, C., Kiesewetter, B., Oosting, S., Passaro, A., Pentheroudakis, G., Piccart, M., Roitberg, F., Tabernero, J., Tarazona, N., Trapani, D., Wester, R., Zarkavelis, G., Zielinski, C., Zygoura, P., Cherny, N.I.
Publicado 2021

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors

por Oosting, S.F., van der Veldt, A.A.M., Fehrmann, R.S.N., Bhattacharya, A., van Binnendijk, R.S., GeurtsvanKessel, C.H., Dingemans, A.-M.C., Smit, E.F., Hiltermann, T.J.N., den Hartog, G., Jalving, M., Westphal, T.T., de Wilt, F., Ernst, S.M., Boerma, A., van Zijl, L., Rimmelzwaan, G.F., Kvistborg, P., van Els, C.A.C.M., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.E.
Publicado 2023

One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

por van der Veldt, A.A.M., Oosting, S.F., Fehrmann, R.S.N., GeurtsvanKessel, C.H., van Binnendijk, R.S., Dingemans, A.-M.C., Smit, E.F., Hiltermann, T.J.N., Hartog, G. den, Jalving, M., Westphal, T.T., Bhattacharya, A., de Wilt, F., Ernst, S.M., Boerma, A., van Zijl, L., Rimmelzwaan, G.F., Kvistborg, P., van Els, C.A.C.M., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.E.
Publicado 2023